Main content

    Amyotrophic and Primary Lateral Sclerosis Clinical Trials

    Sutter Health participates in clinical trials related to Amyotrophic Lateral Sclerosis throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: Determining the Safety of L-Serine in Patients with Amyotrophic Lateral Sclerosis (ALS) at Varied Doses Opens in a new window external site
    Description:The purpose of this study is to determine whether the supplement L-Serine is safe and effective to give to patients with differing severities of ALS.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 3 years.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Marguerite Engel 415-600-3758, Email: EngleM@cpmcri.org

    Title: A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of NCT01709149 In Patients With Amyotrophic Lateral Sclerosis (ALS)Opens in a new window external site
    Description:The purpose of this research study is to evaluate the safety and effectiveness of NCT01709149 in patients with ALS.
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease moderate hand grip weakness. .
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Marguerite Engel 415-600-3758, Email: EngleM@cpmcri.org

    Title: HDE Post-Approval Study (PAS) of NeuRx DPS TM (Diaphragm Pacing System) for ALS. C_FN_Diaphragm Pacing Post Approval Study Opens in a new window external site
    Description: The purpose of this research study is to collect more information about the possible risks and benefits of the NeuRx DPS TM device (Diaphragm Pacing System).
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate diaphragm weakness.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Dallas Forshew, 415-309-5178, Email: ForsheD@cpmcri.org

    > See All Neurology Clinical Trials by Condition